NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Passes Above 50-Day Moving Average of $0.00

Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBYGet Rating) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $2.49. NovaBay Pharmaceuticals shares last traded at $2.34, with a volume of 228,055 shares.

NovaBay Pharmaceuticals Stock Up 4.5 %

The stock has a market capitalization of $4.35 million, a P/E ratio of -13.76 and a beta of 3.47.

Insider Buying and Selling

In other NovaBay Pharmaceuticals news, insider Jeffrey Kunin sold 291,368 shares of NovaBay Pharmaceuticals stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $0.16, for a total transaction of $46,618.88. Following the completion of the transaction, the insider now directly owns 208,632 shares of the company’s stock, valued at $33,381.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its holdings in shares of NovaBay Pharmaceuticals by 103.5% during the second quarter. Renaissance Technologies LLC now owns 409,544 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 208,322 shares during the period. Virtu Financial LLC lifted its holdings in shares of NovaBay Pharmaceuticals by 260.4% during the first quarter. Virtu Financial LLC now owns 163,451 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 118,099 shares during the period. Finally, Altium Capital Management LP bought a new position in shares of NovaBay Pharmaceuticals during the third quarter valued at $121,000. 2.64% of the stock is owned by institutional investors.

About NovaBay Pharmaceuticals

(Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Featured Articles

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.